590 filings
Page 3 of 30
8-K
xi2 0hqci72k6c
14 Aug 17
Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results
12:00am
EFFECT
hlf07s
4 Aug 17
Notice of effectiveness
12:00am
CORRESP
df5sm 2yr7g
1 Aug 17
Correspondence with SEC
12:00am
UPLOAD
eogmtffezr5p
31 Jul 17
Letter from SEC
12:00am
8-K
3ydeoz5hficiurh8
26 Jul 17
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
12:00am
RW
ig23628ur8e0a
25 Jul 17
Registration withdrawal request
12:00am
8-K
23x09mqcpm7 hp0edhx
21 Jul 17
Other Events
12:00am
8-K
gpv3a4 od
17 Jul 17
Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA
12:00am
8-K
biv6xbi20 hr
16 Jun 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
dx0 a9hza2
31 May 17
Departure of Directors or Certain Officers
12:00am
8-K
j659ru8lyoa9qazkld4
22 May 17
Other Events
12:00am
424B5
r4aokqn
18 May 17
Prospectus supplement for primary offering
12:00am
424B5
no10b5igsxs6g h4hwn
18 May 17
Prospectus supplement for primary offering
12:00am
8-K
gmfjmwy1jp3
17 May 17
REPROS THERAPEUTICS CORPORATE PRESENTATION MAY 2017 Dedicated to Treating Male and Female Reproductive Disorders
12:00am
8-K
lxr ut2ca
9 May 17
Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results
12:00am